Eli Lilly’s Zepbound proved more effective than Novo Nordisk’s Wegovy in a new head-to-head trial, though both medications ...

When considering a weight loss medication — or any medication — it’s normal to wonder when the effects will kick in.

Novo Nordisk will present data at the European Congress of Obesity (ECO) from a secondary, post hoc analysis of the SELECT ...

Novo Nordisk boosts Wegovy access with discounts as FDA bans compounded semaglutide drugs and cracks down on weight-loss copycats.

Both medications were prescribed as weekly injections for patients clinically classified as obese, and were recommended ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

The telehealth site will welcome its own small-dose, compounded version of semaglutide, which mimics the function of a GLP-1.

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial.

Weekly 2.4 mg semaglutide was linked to improved liver histology results but did not significantly reduce body pain compared ...

NEW YORK (Reuters) -Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the ... maximum dose of 2.4 mg over 20 weeks.

Weight-Loss Company Noom Pivots to Smaller Doses of Compounded Wegovy By Amina Niasse NEW YORK ... half the FDA-approved maximum dose of 2.4 mg over 20 weeks. Noom said the move is not meant ...